IGIA Pharmaceuticals, Inc (IGIA), a pharmaceutical company based outside of Cincinnati, Ohio, specializing in the development of pharmaceutical products for the treatment of orphan indications or small population indications with an unmet medical need. IGIA has developed novel formulation technology that facilitates clinical studies in infants and children.
IGIA’s current focus is the development of IG-100 (dasatinib), an inhibitor of multiple signaling kinases for the treatment of Noonan syndrome-associated cardiac dysfunction in pediatric patients. IGIA obtained an exclusive world-wide license from Yale University for the novel use of dasatinib for the treatment of pediatric congenital and adult cardiac indications effective 31 March 2017.
IGIA is committed to complete the Phase 2a trial of IG-100 (dasatinib) by Q3 of 2021.